anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for lymphoid lineages, but lacking the potential to differentiate into myeloid and erythroid lineages. Methods are provided for the isolation and culture of this common lymphoid progenitor cell (CLP). The cell enrichment methods employ reagents that specifically recognize CDw127 (IL-7 receptor α); CD117 (c-kit) protein, in conjunction with other markers expressed on lineage committed cells. The murine cells are also characterized as expressing low levels of sca-1 (Ly-6E and Ly-6A). The CLPs are predominantly cycling, blast cells. These cells give rise to B cells, T cells and natural killer cells, as evidenced by their growth and differentiation in vitro and in vivo.
Sertraline is a selective serotonin reuptake inhibitor. Sertraline is FDA approved for the treatment of major depressive disorder, obsessive compulsive disorder, posttraumatic stress disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder in adults. Sertraline is also approved for the treatment of obsessive compulsive disorder in children and adolescents. Pharmacotherapy visits will be scheduled at weeks 9-12, 14, 16, 18, 20 with phone visits at weeks 15, 17, and 19. The psychiatrist will meet for \~30 min. with the youth and parents. Efforts will be made to use the most effective and tolerated SRT dose.
The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.
This group (12 patients) will be given 40Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
Participants received bevacizumab, 15 milligrams (mg) per (/) kilogram (kg), intravenously (IV), on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received 4 to 6 cycles of a standard platinum-containing regimen of chemotherapy: either gemcitabine, 1250 mg/ square meter (m\^2), IV, on Days 1 and 8 of Cycles 1 through 4 or 6, and cisplatin 80 mg/m\^2, IV, on Day 1 of Cycles 1 through 4 or 6; or paclitaxel, 200 mg/m\^2, IV, and carboplatin area under the curve (AUC) 6 mg/ milliliter (ml) multiplied by (\*) minute (min) on Day 1 of Cycles 1 through 4 or 6. The chemotherapy regimen and number of cycles was up to the discretion of the investigator.
PROBLEM TO BE SOLVED: To strengthen the efficacy of a health adjuvant mainly comprising Angelica shikokiana Makino and to improve its ingestion properties. SOLUTION: The objective health adjuvant mainly comprises a powder of Angelica shikokiana Makino a powder of Zizania latifolia (water oat). The ratio of the two components is 50-80% of Angelica shikokiana Makino to 50-20% of the water oat. When Angelica shikokiana Makino and water oat are mixed at a ratio of 8:2, evidently synergistic effect can be observed against allergic rhinitis without any lowering in their phaemacodynamic effects and in addition, the protection and enhancement of systemic physical conditions and smooth ingestion are markedly improved, thereby permitting a long-term intake. According to the present invention, other nutrient auxiliary agents such as usual vitamin preparations can be combined thereto without any trouble. This auxiliary agent can be used in the preparation forms of tablets, granules, capsules and the like in addition to the powder form.
The invention discloses a method for designing an anti-HPV cervical wound dressing. The dressing is a fusion protein designed based on the research of SERPINA3 and IFN-kappa functions by international co-workers and the research of the properties of the two proteins by the laboratory. The specific method is to use the overlap extension PCR technology to obtain a gene fragment of a fusion protein SERPINA 3-IFN-kappa which is covalently linked with the SERPINA3 and the IFN-kappa by taking an amino acid sequence GGSGG as a linker. Cloning target gene into prokaryotic expression vector Pet30 (modified) and carrying out expanded culture, and carrying out affinity chromatography on MBP column to obtain ternary fusion protein MBP-SERPINA 3-IFN-kappa with purity of more than 90%. We verified the inhibition of HSV-1 virus replication by this fusion protein at the cellular and mouse levels. Finally, the fusion protein is proved to be easy to purify, high in activity and free of side effect, and is very suitable for being used as an anti-HPV cervical wound dressing.
The invention discloses laium domesticum flesh jelly and a production method thereof. The production method takes laium domesticum fruits as raw materials; and the following auxiliary materials are added: wallich swallowwort roots, fruits of fruitcose gomphocarpus and cymbidium pendulum stems and leaves, so that the laium domesticum flesh jelly is prepared. Nutritive values of the laium domesticum fruits are fully utilized; moreover, the laium domesticum fruits and the traditional Chinese medicines are mutually matched so as to synergistically enhance the effects; thus, the prepared laium domesticum flesh jelly has the functions of nourishing the liver, benefiting the kidney, promoting urination and eliminating the swelling. Laium domesticum juice is preliminarily fermented by using fruit-wine distiller's yeast, so that a mellow fragrance is added to the final products. Traditional Chinese medicine syrup is preliminarily fermented by using sweet-wine distiller's yeast, so that the bitter and astringent taste of the traditional Chinese medicine syrup is removed; thus, the prepared final products are aromatic, sweet and delicious in taste. The prepared laium domesticum flesh jelly is glittering and translucent in appearance as well as elastic, and has outstanding health-care functions. The laium domesticum flesh jelly is convenient to store, and is capable of obviously improving discomfort of the people with sore and pain in waist and knee caused by long-term staying in humid environment when the laium domesticum flesh jelly is taken for a long term. The laium domesticum flesh jelly is simple in preparation technology, easy to realize, vast in market, and suitable for batch production.
Incarcerated women engage in high rates of sex- and drug-related behavior that place them at risk for HIV. Pre-exposure prophylaxis (PrEP) is an efficacious means of reducing HIV acquisition. There is a general lack of knowledge regarding PrEP among women at elevated risk, and only a small percentage of at-risk women are currently engaged in PrEP care. The period of incarceration represents an opportunity to identify at-risk women, initiate PrEP during incarceration, and establish linkage to community-based PrEP care upon release from incarceration. Further, post-release is a time period that is particularly risky, and there are numerous barriers that may impede linkage to community-based care in the absence of intervention.

To date, very little research has been done to improve linkage to PrEP care among US women. The proposed study will examine the acceptability, feasibility, and preliminary efficacy of a psychoeducation and motivational interviewing intervention to promote PrEP initiation during incarceration, followed by a patient navigator intervention to facilitate linkage to community-based PrEP care upon release from incarceration. The long-term goal of this line of research is to disseminate an efficacious PrEP Care linkage intervention for at-risk women post-release from incarceration. The present proposal seeks to develop intervention materials and conduct a small randomized controlled trial (RCT) of the intervention.
PURPOSE:The titled composition, obtained by dispersing acetaminophen or a pharmaceutical containing the acetaminophen in macrogol and/or propylene glycol, and having fluidity suitable for filling. CONSTITUTION:A composition for filling soft capsules obtained by dispersing <1.5pts.wt., preferably 0.7-1.4pts.wt. acetaminophen or a pharmaceutical containing the acetaminophen, e.g. an antitussive and expectorant such as hydrobromic acid, an antihistaminic agent such as chlorpheniramine or vitaminic agent, in the form of a prepared fine powder in 1pts.wt. macrogol and/or propylene glycol or incorporating both and finely dividing both therein, and dispersing both therein. EFFECT:The acetaminophen can be uniformly dispersed with the specific water- soluble base even in a small amount thereof, and the composition has fluidity suitable for filling.
The whole treatment will last about 12 sessions. Each one lasts about 30 and 40 minutes and will be performed continuously once a week. The frequency may be increased if the level of tonic muscle tension becomes too high.
This study arm might best be described as standard of care. Vulvovaginal dryness will be treated with a daily moisturizer for two weeks, then every other day for the remaining six weeks. Vaginal moisturizer will be applied at night, before sleep and after all sexual activity. Several moisturizers are available, including vaginal DHEA (IntraRosa®). Due to the need for reproducibility, we have decided to use one non-hormonal vaginal moisturizer, Replens™ moisture, which is a vaginal moisturizer consisting primarily of a purified water, glycerin, and mineral oil. Other ingredients included in the formulation are polycarbophyl, carbomer, homopolymer type B, hydrogenated palm oil glyceride, sorbic acid, sodium hydroxide. The moisturizing gel was determined to be a medical device for marketing by the FDA in 2010. It is non-hormonal (unlike vaginal DHEA) and therefore will be more likely to be acceptable by a broader range of oncology providers.
After bariatric surgery, patients with obesity achieve sustainable weight loss, gain in mobility, quality of life and life expectancy. Bariatric surgery can lead to remission of type 2 diabetes or to long term glycaemic control for patients with type 2 diabetes, while medical treatment has a preventive efficacy on micro and macrovascular complications. This has led to the concept of metabolic surgery to treat type 2 diabetes. Despite the benefits, only a small proportion of eligible patients undergo bariatric/metabolic surgery. Powerful antidiabetic medications, self-estimated lack of knowledge by medical professionals and fear of surgical complications are some of the arguments to prefer medical treatment of type 2 diabetes obesity versus metabolic surgery. We have reviewed in this paper the barriers which explain the low referral rate to metabolic surgery. With the point of view of the diabetologist, the general practitioner and the patient, we have addressed them to help clinicians and patients model an evidenced-based patient-oriented medical plan.
The present invention relates to a composition of matter for the time-dependent liberation of therapeutic agents. This composition of matter comprises a polymeric slab and a homogeneously dispersed enzyme which degrades the polymeric slab in the presence of moisture. The therapeutic agent is physically entrapped in the polymeric slab by inclusion during polymerization to form the polymeric slab or by mixture of the therapeutic agent with a liquid form of the polymeric slab and conversion of the liquid to a solid form. The therapeutic agent is not chemically bound to the polymer, and thus release of the agent is immediately effected upon the specific moisture-activated enzymatic degradation of the polymer slab. Moisture for enzymatic activation is provided by the biological surface on which the slab is emplaced, such as the dermal surface. The composition comprises a polymer such as poly (DL-lactide) and an enzyme such as proteinase K together with chlorpheniramine maleate as the therapeutic agent.
This study aimed to explore the relationship between the trajectory of the triglyceride-glucose (TyG) index and the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE) in patients with atrial fibrillation (AF).This prospective study included 1979 patients with AF, who were initially selected from the Kailuan study. Patients of AF were split into four groups according to the value of TyG index. The clinical endpoint was MACCE, including myocardial infarction and ischemic stroke. Cox proportional hazard models were employed to examine the hazard ratio (HR) and 95% confidence interval (CI) for MACCE in various trajectory groups.The mean age of all patients with AF was 67.65 ± 11.15 years, and 1752 (88.53%) were male. Over a median follow-up duration of 5.31 years, in total 227 MACCE were recorded. MACCE cumulative incidence in Quartile 4 (26.96%) was significantly higher than those in other quartiles (P = 0.023). Multivariate Cox proportional hazards regression analysis showed that a higher TyG index (Quartile 4) was significantly and positively linked to MACCE in patients with AF (P = 0.023, HR: 2.103; 95% CI: 1.107-3.994).The evaluated TyG index is significantly associated with an increased risk of MACCE in patients with AF.
The drug dose that taken by the subject is gradually increased to the maximum dose tolerated by the patient according to individualization. Specifically, the initial dose of 80 mg/day was gradually increased to 120 mg/day (80 mg/day in the first week, 120 mg/day in the second week, and a maximum tolerated dose of 160 mg/day). The maximum tolerated dose is 160 mg/day. The dose is administered once daily in a 4-week cycle (3 weeks of dosing and 1 week of rest) and the maximum dose achieved in the first treatment cycle is maintained.At the discretion of the investigator, regorafenib may be delayed or discontinued. Dose adjustments and interruptions due to toxicity are made according to the recommendations specified in the protocol.
The object of the invention is a measurement device and a system for measuring and monitoring information which relates to diabetes care. The purpose of the invention is to motivate a user to perform activities that are required in the care. In a preferred embodiment of the invention a performance levels are determined and the level of a user is based on the activities and/or measurement results of the user. Upon increase in the user's level the user is awarded with e.g. new reminder figure in the device. The motivation of a user to follow care activities is thus increased.
A networked interface appliance for use in the medical arena that simplifies the connectivity of medical diagnostic devices to the portable computers in electronic medical record systems (EMR's). The appliance utilizes location support hardware and software to locate and map various tagged assets within the existing environment. The appliance automatically determines the proximity of nearby portable assets and computing devices, and creates network connection to each. Data obtained from a diagnostic device connected to the appliance is buffered and transmitted to portable computing devices connected to the appliance. Using specific IP addressing, support teams can connect to the appliance to diagnose and correct problems remotely using a local area network, wide area network or the Internet. A video port for remotely controlled video display and for local data acquisition is included. Location data from the appliance can be utilized in improving billing algorithms and workflow analysis. Asset management and location mapping of resources are also supported.
Method for preparing full spectrum cannabis elixir is disclosed. The method comprises steps of breaking cannabis buds into small pieces to form an organic mixture and placing this organic mixture in an oven safe container. The container may be placed in an oven for decarboxylating the organic mixture. The decarboxylated mixture may be mixed and shaken with cold high proof grain alcohol to form an intermediate. Alternatively, the decarboxylated mixture and alcohol is mixed in magical butter or mighty fast herbal infuser to form an intermediate. This intermediate may be filtered using a press or coffee filter. Alcohol content may be removed from this filtered mixture using solvent extractor and water bath. This extract is mixed with organic cold pressed extra virgin coconut oil and lecithin liquid. Lastly, organic cold pressed unrefined hemp seed oil is added and stirred thoroughly to form a full spectrum cannabis extract (Keira's Elixir).
Study group - 50% of the study population will be randomized to the intervention or coaching group in a 1:1 manner after baseline burnout data is obtained. Similarly, 67% of the coaches who volunteer will be randomized to the intervention or coaching group in a 2:1 manner after baseline burnout data is obtained.
Postoperative ctDNA-negative patients will receive chemotherapy for 3 months. The ctDNA dynamic detection and imaging examination will be completed every 3 months, and tumor markers will be detected in each chemotherapy cycle.
Exclusive exposure to light deprived of blue wavelengths from 19.00-08.00 for 14 consecutive days as add-on to treatment as usual (TAU). This will be provided in an ordinary part of the hospital ward with circadian lightening delivered by Chromawiso. This lightening is CE approved. The intervention will be delivered in two separate patient units, each of them will include one living room, one bedroom and a bathroom, area ranging from 58m2- 60 m2. If patients are able to wear blue blocking glasses (amber lenses), they can stay outside the units from 19.00-08.00. Between 08.00-19.00 the patients in the intervention groups can stay inside or outside the units as they wish.
OBJECTIVES: Endothelial-to-mesenchymal transition (EndoMT) is a significant biological phenomenon wherein endothelial cells undergo a loss of their endothelial traits and progressively acquire mesenchymal characteristics. Consequently, this transformation leads to both a compromised ability to maintain lumen permeability and alterations in vascular structure, which hampers the preservation of blood-brain barrier integrity. This study aimed to investigate inflammation-induced EndoMT and its etiology, with the goal of impeding the infiltration of peripheral inflammation into the central nervous system.
MATERIALS AND METHODS: Lipolysaccharide (LPS) was administered intraperitoneally to mice several times to establish a chronic inflammatory model. A cellular inflammatory model was established by LPS in human brain microvascular endothelial cells (HBMECs). The mRNA expressions of inflammatory cytokines interleukin-1β (IL-1β) and IL-6 were detected by real-time polymerase chain reaction (PCR). Immunofluorescence staining of platelet endothelial cell adhesion molecule-1 (CD31) and alpha smooth muscle actin (α-SMA) was conducted to assess the level of EndoMT. The expression levels of Occludin, zona occludens protein 1 (ZO-1), Sestrin2, microtubule-associated protein1 light chain 3 (LC3) and inducible nitric oxide synthase (iNOS) were detected by western blotting.
RESULTS: LPS treatment induced the downregulation of ZO-1 and Occludin, which was accompanied by the elevated expressions of iNOS, α-SMA, Sestrin2 and LC3-II in the mouse cortex and HBMECs. Mechanistically, the knockdown of Sestrin2 in HBMECs exacerbated the EndoMT induced by LPS treatment, while the overexpression of Sestrin2 inhibited this process. Moreover, the induction of autophagy by rapamycin rescued the EndoMT induced by Sestrin2 knockdown.
CONCLUSION: This study revealed that Sestrin2 inhibited endothelial inflammation and EndoMT via enhanced autophagy, which may provide a potential drug target for cerebrovascular inflammatory injury.
The study will include a total of 30 patients who will be diagnosed with AC based on clinical evaluation by physicians from various clinical departments, including physical medicine and rehabilitation, and orthopedics. The diagnosis will be confirmed by two experienced radiologists specializing in musculoskeletal imaging. Based on clinical evaluation and MRI findings, a control group of 34 individuals without suspected AC will be included. MRI imaging will be performed using a 3 Tesla MRI scanner. Sonoelastography will be performed using a Siemens Acuson-S2000 ultrasound device with a 9L4 (4-9 MHz) linear probe and the Virtual Touch Quantification (VTQ/ARFI) method. Shear wave elastography will be applied to the IGHCC to obtain the mean shear wave velocity (SWV) values. The contribution of sonoelastography in the diagnosis of adhesive capsulitis in patients with a clinical prediagnosis of adhesive capsulitis (AC) and inferior glenohumeral capsuloligamentous complex (IGHCC) involvement will be investigated.
FIELD: medicine, dressing for surgery, dermatology, obstetrics, gynecology, first aid. SUBSTANCE: suggested medicinal bandage for treating wounds, burns, ulcers, bedsores and first aid contains successively hydrophobic atraumatic permeable layer, curative layer, that out of polymeric film and external protective air-penetrable sorption layer above the mentioned ones. Moreover, curative layer and that out of polymeric film are designed to be coaxially perforated. The present bandage increases curative efficiency of dressing due to more complete application of medicinal preparation into injured area and more complete exudate outflow that leads to lower wound traumaticity. EFFECT: decreased frequency of dressing procedures. 8 cl, 6 ex